Septal reduction therapy using nonalcohol agent in hypertrophic obstructive cardiomyopathy: Single center experience

Asil S., Kaya B., CANPOLAT U., YORGUN H., Sahiner L., ÇÖTELİ C., ...More

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, vol.92, no.3, pp.557-565, 2018 (SCI-Expanded) identifier identifier identifier


Aims: Percutaneous septal reduction therapy by either alcohol or nonalcohol agents is an alternative approach to surgery in drug-refractory symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM). Nonalcohol agents have some advantages and disadvantages over alcohol during the procedure. Nowadays, a novel non-alcohol agent, named as Ethylene-vinyl alcohol (EVOH) copolymer (Onyx (R) and Squid (R)), is used during septal ablation. Thus, in this study, we aimed to evaluate both acute and long-term efficacy and safety profile of EVOH during septal ablation in HOCM.